CA030-001
03 Dec 2020
Trial Summary
Phase I/ II first in human study of BMS-986249 (CTLA Probody) alone and in combination with nivolumab in advanced solid tumours.
Acronym:
CA030-001
ACTRN/NCT /ethics:
NCT03369223
Scientific title:
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread
Sponsor / Cooperative group:
BMS
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2017-12-05 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |